Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.

Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, Klein SL, Calabresi PA, Gocke AR.

J Neuroimmunol. 2014 May 15;270(1-2):13-21. doi: 10.1016/j.jneuroim.2014.03.007. Epub 2014 Mar 11.

PMID:
24680062
2.

Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.

Ottenlinger F, Schwiebs A, Pfarr K, Wagner A, Grüner S, Mayer CA, Pfeilschifter JM, Radeke HH.

Eur J Immunol. 2016 Apr;46(4):941-51. doi: 10.1002/eji.201545805. Epub 2016 Jan 13.

3.

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.

Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.

4.

FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.

Blanc CA, Rosen H, Lane TE.

J Neuroinflammation. 2014 Aug 20;11:138. doi: 10.1186/s12974-014-0138-y.

5.

Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.

Metzler B, Gfeller P, Wieczorek G, Li J, Nuesslein-Hildesheim B, Katopodis A, Mueller M, Brinkmann V.

Int Immunol. 2008 May;20(5):633-44. doi: 10.1093/intimm/dxn023. Epub 2008 Mar 14.

PMID:
18343890
6.

Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.

Fujiwara M, Anstadt EJ, Khanna KM, Clark RB.

Clin Immunol. 2015 May;158(1):103-13. doi: 10.1016/j.clim.2015.03.018. Epub 2015 Mar 28.

7.

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Brinkmann V.

Br J Pharmacol. 2009 Nov;158(5):1173-82. doi: 10.1111/j.1476-5381.2009.00451.x. Epub 2009 Oct 8. Review.

8.

Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.

Imeri F, Fallegger D, Zivkovic A, Schwalm S, Enzmann G, Blankenbach K, Meyer zu Heringdorf D, Homann T, Kleuser B, Pfeilschifter J, Engelhardt B, Stark H, Huwiler A.

Neuropharmacology. 2014 Oct;85:314-27. doi: 10.1016/j.neuropharm.2014.05.012. Epub 2014 May 23.

PMID:
24863045
9.

FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.

Hofmann M, Brinkmann V, Zerwes HG.

Int Immunopharmacol. 2006 Dec 20;6(13-14):1902-10. Epub 2006 Aug 30.

PMID:
17161343
10.

FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.

Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, Chiba K.

Cell Mol Immunol. 2005 Dec;2(6):439-48.

11.

Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.

Chiba K, Kataoka H, Seki N, Shimano K, Koyama M, Fukunari A, Sugahara K, Sugita T.

Int Immunopharmacol. 2011 Mar;11(3):366-72. doi: 10.1016/j.intimp.2010.10.005. Epub 2010 Oct 16.

PMID:
20955831
12.

Impact of sphingosine 1-phosphate modulation on immune outcomes.

Pinschewer DD, Brinkmann V, Merkler D.

Neurology. 2011 Feb 22;76(8 Suppl 3):S15-9. doi: 10.1212/WNL.0b013e31820d9596. Review.

PMID:
21339486
13.

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.

Papadopoulos D, Rundle J, Patel R, Marshall I, Stretton J, Eaton R, Richardson JC, Gonzalez MI, Philpott KL, Reynolds R.

J Neurosci Res. 2010 Feb 1;88(2):346-59. doi: 10.1002/jnr.22196.

PMID:
19658199
15.

Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.

Johnson TA, Lapierre Y, Bar-Or A, Antel JP.

Arch Neurol. 2010 Dec;67(12):1449-55. doi: 10.1001/archneurol.2010.312.

PMID:
21149809
16.

The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.

Sawicka E, Dubois G, Jarai G, Edwards M, Thomas M, Nicholls A, Albert R, Newson C, Brinkmann V, Walker C.

J Immunol. 2005 Dec 15;175(12):7973-80.

17.

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L.

Neurology. 2008 Oct 14;71(16):1261-7. doi: 10.1212/01.wnl.0000327609.57688.ea.

PMID:
18852441
18.

FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.

Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph GJ, Bromberg JS.

J Clin Invest. 2003 Mar;111(5):627-37.

19.

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.

Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, Milstien S, Spiegel S.

Blood. 2007 Feb 1;109(3):1077-85. Epub 2006 Sep 28.

20.

Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.

Hla T, Brinkmann V.

Neurology. 2011 Feb 22;76(8 Suppl 3):S3-8. doi: 10.1212/WNL.0b013e31820d5ec1. Review.

PMID:
21339489

Supplemental Content

Support Center